NCT02997761

Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia

CompletedPHASE2INTERVENTIONAL

Trial Details

Start: 2017-06-27Est. Completion: 2025-07-17

Enrollment target: 19 participants

Locations

USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

B-AllAcute Lymphoblastic Leukemia

Background: Chimeric antigen receptor T-cell (CART) therapy is a form of immunotherapy which can be used to treat peopl…

Los Angeles, United StatesEst. completion Dec 31, 2026

Obstructive Hypertrophic Cardiomyopathy (oHCM)

The purpose of this study is to compare the efficacy and safety of aficamten (CK-3773274) compared with metoprolol succi…

Anchorage, United StatesCompleted Feb 28, 2025

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.